Literature DB >> 6260835

Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement.

A L Frank, J Puck, B J Hughes, T R Cate.   

Abstract

A modified microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses was developed. Use of continuous cell lines (Madin-Darby canine kidney and LLC-MK2), hemagglutination for virus detection, and transfer plates and other microtiter equipment resulted in a highly mechanized technique suitable for titrating large numbers of sera easily and relatively inexpensively. Titers of heat-inactivated human sera were enhanced 0.5 to 3.5 log2 by addition of fresh hamster or human serum to the test. Seroconversion rates and identification of seronegative persons were not changed by fresh serum enhancement, but the magnitude of seroconversion was often increased and the distribution of positive titers was broadened. For influenza A and B, seroconversion rates in the microneutralization test were equivalent to those obtained in rhesus monkey kidney tube neutralization tests. For influenza B, seroconversion rates by micro-neutralization were almost double those obtained with the hemagglutination inhibition test, but the rates were similar for influenza A/USSR (H1N1). Preexisting microneutralization titers correlated well with resistance of infection with influenza B. Limited experience with parainfluenza 1 and 2 was similar to previously reported findings with the tube neutralization test.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6260835      PMCID: PMC273601          DOI: 10.1128/jcm.12.3.426-432.1980

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Sensitive neutralization test for virus antibody. 1. Mumps antibody.

Authors:  H Sato; P Albrecht; J T Hicks; B C Meyer; F A Ennis
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

2.  Automated microtransfer technique for the assay of poliovirus- and mumps virus-neutralizing antibodies.

Authors:  R E Mayner; D J McDorman; B C Meyer; P D Parkman
Journal:  Appl Microbiol       Date:  1974-12

3.  A new micro-neutralization test for antibody determination and typing of parainfluenza and influenza viruses.

Authors:  H Wulff; J Soeken; J D Poland; T D Chin
Journal:  Proc Soc Exp Biol Med       Date:  1967 Aug-Sep

4.  Enhancement of hemagglutination inhibition by complement.

Authors:  P W Reno; E M Hoffmann
Journal:  Infect Immun       Date:  1972-12       Impact factor: 3.441

5.  Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness.

Authors:  J Mills; J E Van Kirk; P F Wright; R M Chanock
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

6.  Piggy-back microtransfer technique.

Authors:  L W Catalano; D A Fuccillo; J L Sever
Journal:  Appl Microbiol       Date:  1969-12

7.  Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody.

Authors:  P A Gross; A E Davis
Journal:  J Clin Microbiol       Date:  1979-09       Impact factor: 5.948

8.  Complement components required for virus neutralization by early immunoglobulin antibody.

Authors:  W D Linscott; W E Levinson
Journal:  Proc Natl Acad Sci U S A       Date:  1969-10       Impact factor: 11.205

9.  Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans.

Authors:  E D Kilbourne
Journal:  J Infect Dis       Date:  1976-10       Impact factor: 5.226

Review 10.  Neutralization of animal viruses.

Authors:  B Mandel
Journal:  Adv Virus Res       Date:  1978       Impact factor: 9.937

View more
  44 in total

1.  Antigenic distance measurements for seasonal influenza vaccine selection.

Authors:  Zhipeng Cai; Tong Zhang; Xiu-Feng Wan
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

2.  A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults.

Authors:  Robert L Atmar; Wendy A Keitel; Thomas R Cate; Flor M Munoz; Fred Ruben; Robert B Couch
Journal:  Vaccine       Date:  2007-05-22       Impact factor: 3.641

3.  Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.

Authors:  Robert B Couch; Patricia Winokur; Rebecca Brady; Robert Belshe; Wilbur H Chen; Thomas R Cate; Bryndis Sigurdardottir; Amy Hoeper; Irene L Graham; Robert Edelman; Fenhua He; Diane Nino; Jose Capellan; Frederick L Ruben
Journal:  Vaccine       Date:  2007-09-14       Impact factor: 3.641

4.  Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.

Authors:  I Mbawuike; Y Zang; R B Couch
Journal:  Vaccine       Date:  2007-01-24       Impact factor: 3.641

5.  Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system.

Authors:  Y Okuno; K Tanaka; K Baba; A Maeda; N Kunita; S Ueda
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

6.  Annual vaccination against influenza virus hampers development of virus-specific CD8⁺ T cell immunity in children.

Authors:  Rogier Bodewes; Pieter L A Fraaij; Martina M Geelhoed-Mieras; Carel A van Baalen; Harm A W M Tiddens; Annemarie M C van Rossum; Fiona R van der Klis; Ron A M Fouchier; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

7.  Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans.

Authors:  Kristine L Bucasas; Luis M Franco; Chad A Shaw; Molly S Bray; Janet M Wells; Diane Niño; Nancy Arden; John M Quarles; Robert B Couch; John W Belmont
Journal:  J Infect Dis       Date:  2011-02-28       Impact factor: 5.226

8.  Swine Influenza Virus PA and Neuraminidase Gene Reassortment into Human H1N1 Influenza Virus Is Associated with an Altered Pathogenic Phenotype Linked to Increased MIP-2 Expression.

Authors:  Daniel Dlugolenski; Les Jones; Elizabeth Howerth; David Wentworth; S Mark Tompkins; Ralph A Tripp
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

9.  Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.

Authors:  Robert B Couch; Robert L Atmar; Thomas R Cate; John M Quarles; Wendy A Keitel; Nancy H Arden; Janet Wells; Diane Niño; Philip R Wyde
Journal:  Vaccine       Date:  2009-07-14       Impact factor: 3.641

10.  Effects of social and family factors on viral respiratory infection and illness in the first year of life.

Authors:  G Gardner; A L Frank; L H Taber
Journal:  J Epidemiol Community Health       Date:  1984-03       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.